Baxter International Inc (NYSE:BAX) SVP Scott Pleau sold 27,197 shares of Baxter International stock in a transaction dated Monday, June 25th. The stock was sold at an average price of $73.57, for a total value of $2,000,883.29. Following the transaction, the senior vice president now owns 47,363 shares in the company, valued at $3,484,495.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

BAX opened at $73.84 on Friday. Baxter International Inc has a 1 year low of $58.81 and a 1 year high of $75.62. The stock has a market capitalization of $39.52 billion, a price-to-earnings ratio of 28.28, a PEG ratio of 1.91 and a beta of 0.81. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.03 and a current ratio of 2.63.

Baxter International (NYSE:BAX) last released its quarterly earnings results on Thursday, April 26th. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.08. Baxter International had a return on equity of 15.70% and a net margin of 7.75%. The firm had revenue of $2.68 billion for the quarter, compared to the consensus estimate of $2.62 billion. During the same quarter last year, the business posted $0.58 EPS. The company’s revenue for the quarter was up 8.2% on a year-over-year basis. analysts expect that Baxter International Inc will post 2.89 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, July 2nd. Shareholders of record on Friday, June 1st will be paid a $0.19 dividend. This is an increase from Baxter International’s previous quarterly dividend of $0.16. The ex-dividend date is Thursday, May 31st. This represents a $0.76 annualized dividend and a dividend yield of 1.03%. Baxter International’s dividend payout ratio (DPR) is currently 30.65%.

Several research analysts have weighed in on the company. Zacks Investment Research lowered Baxter International from a “buy” rating to a “hold” rating in a report on Thursday, May 31st. ValuEngine lowered Baxter International from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. Bank of America lifted their target price on Baxter International from $73.00 to $83.00 and gave the stock a “buy” rating in a report on Tuesday, May 22nd. Finally, Piper Jaffray Companies assumed coverage on Baxter International in a report on Thursday, May 17th. They set an “overweight” rating and a $77.00 target price on the stock. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Baxter International presently has an average rating of “Buy” and a consensus target price of $73.25.

Several large investors have recently added to or reduced their stakes in BAX. Robecosam AG acquired a new stake in shares of Baxter International in the fourth quarter valued at about $103,000. Ostrum Asset Management acquired a new stake in shares of Baxter International in the first quarter valued at about $121,000. IHT Wealth Management LLC increased its position in shares of Baxter International by 71.9% in the first quarter. IHT Wealth Management LLC now owns 2,462 shares of the medical instruments supplier’s stock valued at $156,000 after acquiring an additional 1,030 shares during the last quarter. Truewealth LLC acquired a new stake in shares of Baxter International in the fourth quarter valued at about $159,000. Finally, Summit Trail Advisors LLC increased its position in shares of Baxter International by 6,961.5% in the first quarter. Summit Trail Advisors LLC now owns 161,427 shares of the medical instruments supplier’s stock valued at $161,000 after acquiring an additional 159,141 shares during the last quarter. 83.44% of the stock is currently owned by institutional investors and hedge funds.

About Baxter International

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Insider Buying and Selling by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.